EQRX · Eqrx, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 |
|---|---|---|
| Revenue | - | - |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| R&D | $228.50M | $224.39M |
| SG&A | $127.38M | $25.69M |
| Total Operating Expenses | $355.88M | $250.08M |
| D&A | $935.0K | $338.0K |
| Operating Income | ($355.88M) | ($250.08M) |
| Interest Expense | - | - |
| Income Tax | $0 | $0 |
| Net Income | ($169.09M) | ($249.98M) |
| EPS - Basic | ($0.36) | ($1.81) |
| EPS - Diluted | ($0.36) | ($1.81) |
Balance Sheet
| Line item | FY 2022 | FY 2021 |
|---|---|---|
| Cash & Equivalents | $494.14M | $1.68B |
| Accounts Receivable | - | - |
| Inventory | - | - |
| Accounts Payable | $19.95M | $7.64M |
| Current Assets | $1.43B | $492.28M |
| Total Assets | $1.46B | $500.53M |
| Current Liabilities | $51.92M | $14.20M |
| Long-term Debt | - | - |
| Total Liabilities | $66.15M | $18.45M |
| Stockholders' Equity | $1.39B | $482.08M |
| Retained Earnings | ($527.59M) | ($258.49M) |
Cash Flow
| Line item | FY 2022 | FY 2021 |
|---|---|---|
| Operating Cash Flow | ($287.27M) | ($241.51M) |
| Investing Cash Flow | ($897.28M) | ($2.98M) |
| Financing Cash Flow | $139.0K | $715.48M |
| CapEx | $1.13M | $2.98M |
| Free Cash Flow | ($288.40M) | ($244.49M) |
Ratios
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Profitability | ||
| Gross margin | - | - |
| Operating margin | - | - |
| EBITDA margin | - | - |
| Net margin | - | - |
| Free cash flow margin | - | - |
| FCF / Net income | 1.71 | 0.98 |
| R&D / Revenue | - | - |
| SG&A / Revenue | - | - |
| Effective tax rate | - | - |
| Return on assets | -11.6% | -49.9% |
| Return on equity | -12.2% | -51.9% |
| Return on invested capital | - | - |
| Liquidity | ||
| Current ratio | 27.51 | 34.68 |
| Quick ratio | 27.51 | 34.68 |
| Cash ratio | 9.52 | 118.24 |
| Leverage | ||
| Debt / Equity | - | - |
| Debt / Assets | - | - |
| Debt / EBITDA | - | - |
| Interest coverage | - | - |
| Equity multiplier | 1.05 | 1.04 |
| Liabilities / Assets | 0.05 | 0.04 |
| Efficiency | ||
| Asset turnover | - | - |
| Inventory turnover | - | - |
| Days sales outstanding | - | - |
| Days inventory outstanding | - | - |
| Days payable outstanding | - | - |
| Cash conversion cycle | - | - |
| Valuation | ||
| P / E | - | - |
| P / B | - | - |
| P / S | - | - |
| EV / EBITDA | - | - |
| Growth | ||
| Revenue growth (YoY) | - | - |
| Revenue CAGR (3y) | - | - |
| Revenue CAGR (5y) | - | - |
| Gross profit growth (YoY) | - | - |
| Operating income growth (YoY) | -42.3% | - |
| Net income growth (YoY) | 32.4% | - |
| EPS growth (YoY) | 80.1% | - |
| EPS CAGR (3y) | - | - |
| EPS CAGR (5y) | - | - |
| FCF growth (YoY) | -18.0% | - |
| FCF CAGR (5y) | - | - |
| Book value growth (YoY) | 188.1% | - |
Stability scores
Piotroski F-score
FY 2022 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✗Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing EQRx against the 5 most active filers in the same SIC group.